Correspondence to Dr Annette H M van der Helm-van Mil, Department of Rheumatology, Leiden University Medical Center, P.O. Box 9600, Leiden 2300 RC, The Netherlands; AvdHelm{at}lumc.nl Background ...
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology Unit, “Attikon” University Hospital, Athens 12462, Greece; afanour{at}med.uoa.gr Our objective was to update the EULAR ...
Objective We aimed to understand the role of the transcriptional co-factor Yes-associated protein (Yap) in the molecular pathway underpinning the pathogenic transformation of synovial fibroblasts (SF) ...
Correspondence to Dr Peter Kvacskay, Department of Internal Medicine V Hematology Oncology Rheumatology, University Hospital Heidelberg, Heidelberg 69120, Germany; peter.kvacskay{at}med.uni-heidelberg ...
Correspondence to Professor Daniel Aletaha, Department of Medicine III, Medical University of Vienna, Wien 1090, Austria; daniel.aletaha{at}meduniwien.ac.at Objectives To investigate whether treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback